Torrent Pharma FYQ1 PAT rises 3.3% as JB integration costs & higher finance charges weigh on earnings

The drugmaker reported a consolidated profit after tax of ₹566 crore for the first quarter of FY27 compared with ₹548 crore a year earlier

| Photo Credit:

cueapi

Torrent Pharmaceuticals, the flagship company of Gujarat-based Torrent Group, reported a modest 3.3 per cent year-on-year increase in consolidated net profit for the first quarter of FY27 as higher finance costs, depreciation and one-time integration-related expenses linked to the JB Pharma acquisition offset the benefit of a sharp rise in revenue.The drugmaker reported a consolidated profit after tax of ₹566 crore for the first quarter of FY27 compared with ₹548 crore a year earlier, while revenue from operations surged 55 per cent to ₹4,921 crore, driven primarily by the inclusion of JB Pharma. Operating EBITDA before exceptional items rose 61 per cent to ₹1,664 crore, with margin improving to 33.8 per cent from 32.5 per cent a year ago.The quarter included ₹21 crore of exceptional expenses, comprising regulatory and statutory costs related to the JB Pharma acquisition and merger as well as inventory write-offs following a fire at an erstwhile JB Pharma warehouse. The company also absorbed higher depreciation and finance costs following the acquisition, limiting growth in the bottom line despite strong operating performance.Growth driverExcluding JB Pharma, Torrent’s standalone business continued to post healthy growth, with revenue rising 17 per cent to ₹3,720 crore and operating EBITDA increasing 20 per cent to ₹1,240 crore. India remained the biggest growth driver, with revenue rising 19 per cent to ₹2,157 crore, outperforming the domestic pharmaceutical market’s 12 per cent growth, according to AIOCD Pharmatrac data. Torrent said it is now ranked No. 1 in the Indian cardiac market, while its generic Semaglutide franchise captured a 36 per cemt market share across oral and injectable formulations during the quarter.International markets also delivered a mixed performance. Revenue from the US grew 36 per cent on new product launches and one-time opportunities, while Brazil reported 27 per cent growth despite a one-time reduction in channel inventory. Germany remained weak as supply disruptions at a third-party manufacturer and lower tender offtake continued to weigh on sales.The acquired JB Pharma business posted revenue of ₹1,201 crore, up 10 per ent, while operating EBITDA climbed 34 per cent to ₹424 crore, aided by strong growth in the domestic prescription business and CDMO operations.Published on July 30, 2026